A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. THE ROLE OF NEW ORAL ANTICOAGULANTS. Part I
https://doi.org/10.24884/2072-6716-2017-18-2-37-44
Abstract
The article highlights the burden of the venous thromboembolism (VTE) in clinical practice as one of the most frequent cause of cardiovascular death and disabling embolic stroke worldwide. The author compares the traditional use of VKA antagonists and new class of oral anticoagulants— direct thrombin and factor Xa inhibitors (dabigatran, rivaroxaban, apixaban) for VTE treatment and prevention. The results of most significant randomized clinical trials in VTE area and the latest international guidelines are also discussed.
About the Author
V. I. Shalnev
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. 2015. Т. 9. № 4. С. 4–46. [Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu I profilaktike venoznikh tromboembolicheskich oslojnenii. Flobologiya, 2015, Vol. 9 (4), рр. 4–46. (In Russ.)].
2. Mazzolai L., Aboyans V., Ageno W. et al. Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document from European Society of Cardiology, Working Groups of Aorta and Peripheral Circulation and Pulmonary Circulation. Eur. Heart J., 2017, Feb 17 [Epub ahead of print.
3. Thrombosis: a major contributor to the global disease burden. ISTH Steering Committee for World Thrombois Day. J. Thromb. Haemost., 2014, Vol. 12, рр. 1580–1590.
4. White R. The Epidemiology of Venous Thromboembolism. Circulation, 2003, Vol. 107, рр. 14–18.
5. Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, Vol. 117, рр. 25–46.
6. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, Vol. 367, рр. 1903–1912.
7. Oden A., Fahlen M., Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thrombosis Research., 2006, Vol. 117, рр. 493–499.
8. Gladstone D.J., Bui E., Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009, Vol. 40, рр. 235–240.
9. Connolly S.J., Ezekowitz, M., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2009, Vol. 361, рр. 1139–1151.
10. Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 883–891.
11. Granger C. B., Alexander J. H., McMurray J.V. et al. for the ARISTOTLE Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 981–992.
12. Romanelli R.J., Nolting L.R., Dolginsky M. et al. Dabigatran Versus Warfarin for Atrial Fibrillation in RealWorld Clinical Practice. Circulation: Cardiovascular Quality and Outcomes. 2016, Vol. 9, рр. 115.
13. Yao X., Abraham N.S., Sangaralingham L.R. et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J. of Am. Heart Association, 2016, Vol. 5, e003725.
14. 2016 ESC Guidelines for the management of atrial fibrillation. Eur. Heart J. 2016, Vol. 37, рр. 2893–2962.
15. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation. Eur. Heart J., 2016, Vol. 37, рр. 267–315.
16. Mega J.l., Braunwald E., Wiviott D.S. et al. for the ATLAS— TIMI-51 Investigators/Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New Engl. J. Med., 2012, Vol. 366, рр. 9–19.
Review
For citations:
Shalnev V.I. A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. THE ROLE OF NEW ORAL ANTICOAGULANTS. Part I. EMERGENCY MEDICAL CARE. 2017;18(2):37-44. (In Russ.) https://doi.org/10.24884/2072-6716-2017-18-2-37-44
Views:
616
Email this article 